RYKINDO
Clinical safety rating
cautionComprehensive clinical and safety monograph for RYKINDO (RYKINDO).
RYKINDO (pitolisant) is a selective histamine H3 receptor antagonist/inverse agonist. It enhances the activity of brain histaminergic neurons by blocking H3 autoreceptors, thereby increasing histamine release. This promotes wakefulness and reduces excessive daytime sleepiness.
| Metabolism | Primarily metabolized by CYP3A4, with minor contributions from CYP2D6 and CYP1A2. Undergoes glucuronidation and oxidation. Major metabolite is inactive. |
| Excretion | RYKINDO (risperidone long-acting injectable) is primarily excreted via urine (70%) as active moiety (risperidone and 9-hydroxyrisperidone), with approximately 14% excreted in feces. Renal clearance accounts for ~60% of total clearance. |
| Half-life | Terminal elimination half-life of risperidone is approximately 3-6 hours, and for 9-hydroxyrisperidone (paliperidone) 21-30 hours in extensive metabolizers. With the long-acting formulation, effective half-life for the release profile is 3-6 days due to slow absorption from gluteal muscle. |
| Protein binding | Risperidone is 90% bound to plasma proteins (albumin and alpha-1-acid glycoprotein); 9-hydroxyrisperidone is 77% bound. |
| Volume of Distribution | Volume of distribution at steady state is approximately 1-2 L/kg, indicating extensive tissue distribution, with a central volume of 0.5-1.5 L/kg. |
| Bioavailability | Intramuscular injection (long-acting): relative bioavailability is approximately 100% compared to oral solution after 4 weeks. Oral immediate release: absolute bioavailability is 66-70% (first-pass metabolism). |
| Onset of Action | Intramuscular injection: therapeutic effect typically observed within 3-4 weeks (requires oral supplementation for first 3 weeks). Oral immediate release: onset of antipsychotic effect occurs within 1-2 hours post-dose. |
| Duration of Action | Intramuscular depot: duration of action is 2 weeks for the recommended dosing interval (every 2 weeks). Clinical effect is maintained over the dosing interval. Oral: duration of effect is 12-24 hours necessitating daily dosing. |
| Molecular Weight | 840.56 |
10 mg orally once daily, increased to 20 mg orally once daily after 1 week if tolerated, with a maximum of 20 mg/day.
| Dosage form | FOR SUSPENSION, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min). For severe renal impairment (eGFR <30 mL/min), reduce starting dose to 5 mg once daily, with a maximum of 10 mg/day. |
| Liver impairment | For Child-Pugh class A or B: no adjustment needed. For Child-Pugh class C: contraindicated. |
| Pediatric use | Not approved for use in pediatric patients below 18 years of age. |
| Geriatric use | No specific dose adjustment recommended, but elderly patients may be more sensitive to adverse effects; initiate at 5 mg once daily and titrate cautiously. |
| 1st trimester | Avoid in first trimester unless no safer alternative; case reports of optic nerve hypoplasia and other anomalies. |
| 2nd trimester | Use only if potential benefit justifies risk; may cause fetal neurobehavioral effects. |
| 3rd trimester | Avoid in third trimester; risks include neonatal withdrawal, pulmonary hypertension, and neurobehavioral disturbances. |
Clinical note
Comprehensive clinical and safety monograph for RYKINDO (RYKINDO).
| Placental transfer | Crosses placenta; cord blood levels approximately 50% of maternal serum levels. |
| Breastfeeding | Excreted into breast milk in low concentrations; monitor infant for sedation and poor feeding. Use only if essential. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | RYKINDO (risperidone) is classified as Pregnancy Category C. First trimester: limited human data; animal studies show increased fetal deaths and cleft palate at high doses. Second and third trimesters: risk of extrapyramidal symptoms and withdrawal in neonates after third trimester exposure. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, weight gain, glucose levels (risk of metabolic changes). Fetal monitoring: ultrasound for growth and development if used during pregnancy. Neonatal monitoring: assess for extrapyramidal symptoms, sedation, withdrawal, and feeding difficulties. |
| Fertility Effects | Risperidone can increase serum prolactin levels via dopamine D2 receptor blockade, potentially causing menstrual irregularities, anovulation, and reduced fertility in women. In men, hyperprolactinemia may lead to decreased libido, erectile dysfunction, and impaired spermatogenesis. Effects are reversible upon dose reduction or discontinuation. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
Hypersensitivity to paliperidone or risperidoneConcurrent use with drugs prolonging QT interval or causing electrolyte disturbances
| Precautions | Prolongation of QT interval: Avoid use in patients with known QT prolongation or concurrent use of QT-prolonging drugs, Hepatic impairment: Contraindicated in severe hepatic impairment; dose adjustment required in moderate impairment, Renal impairment: Not recommended in severe renal impairment (CrCl < 30 mL/min), Psychiatric effects: May cause anxiety, insomnia, or irritability; monitor for psychiatric symptoms, Driving impairment: Caution when driving until individual response is established |
| Food/Dietary | RYKINDO must be taken with food (at least 350 calories) to enhance absorption. Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4 and can increase lurasidone plasma concentrations. High-fat meals may further increase absorption. Avoid alcohol as it may exacerbate CNS depression. |
| Clinical Pearls | RYKINDO (lurasidone) is an atypical antipsychotic with lower weight gain and metabolic side effects compared to olanzapine or clozapine. It requires administration with at least 350 calories of food to increase absorption; take AUC ↓ 50% if administered on an empty stomach. Monitor for akathisia, especially in elderly patients. Contraindicated with strong CYP3A4 inducers (e.g., carbamazepine, rifampin) and inhibitors (e.g., ketoconazole, clarithromycin). QT prolongation risk co-administered with other QT-prolonging drugs. Dose adjustment needed for moderate to severe hepatic impairment (Child-Pugh B or C). |
| Patient Advice | Take RYKINDO with food (at least 350 calories) to ensure proper absorption. · Do not stop taking this medication suddenly; consult your doctor before discontinuing. · Avoid grapefruit and grapefruit juice as they can increase side effects. · Report symptoms such as restlessness, muscle stiffness, fever, or confusion immediately. · May cause dizziness or drowsiness; avoid driving until you know how it affects you. · Inform your doctor about all other medications, including over-the-counter and herbal supplements. · This medication may increase blood sugar and cholesterol; regular monitoring is needed. |
Loading safety data…